Big Pharma's Appetite for Biologics Platforms Fuels New Company Creation
This article was originally published in Start Up
Executive Summary
With the industry on the cusp of a "me-better" era in biotherapies, Big Pharma has more incentive than ever to invest in novel platforms that can build better biologics. Start-Up profiles ArGEN-X, Crescendo Biologics, Oligasis and Open Monoclonal Technology